

1 **Genomic characterization of invasive typhoidal and non-typhoidal *Salmonella* in**  
2 **southwestern Nigeria**

3

4 Odion O. Ikhimiukor<sup>1</sup>, Anderson O. Oaikhen<sup>1</sup>, Ayorinde O. Afolayan<sup>1</sup>, Abayomi Fadeyi<sup>2</sup>,  
5 Aderemi Kehinde<sup>3</sup>, Veronica O Ogunleye<sup>3</sup>, Aaron O. Aboderin<sup>4</sup>, Oyinlola O. Oduyebo<sup>5</sup>,  
6 Charles J. Elikwu<sup>6</sup>, Erkison Ewomazino Odih<sup>1</sup>, Ifeoluwa Komolafe<sup>1</sup>, Silvia Argimón<sup>7</sup>,  
7 Abiodun Egwuenu<sup>8</sup>, Ini Adebisi<sup>3</sup>, Oluwadamiloa A. Sadare<sup>6</sup>, Tochi Okwor<sup>8</sup>, Mihir Kekre<sup>7</sup>,  
8 Anthony Underwood<sup>7</sup>, Chikwe Ihekweazu<sup>8</sup>, David M. Aanensen<sup>7</sup> and Iruka N. Okeke<sup>1</sup>

9

10

11 <sup>1</sup>Global Health Research Unit for the Genomic Surveillance of Antimicrobial Resistance,  
12 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan,  
13 Ibadan, Oyo State, Nigeria.

14 <sup>2</sup>Department of Medical Microbiology and Parasitology, University of Ilorin, Ilorin, Kwara  
15 State, Nigeria.

16 <sup>3</sup>Department of Medical Microbiology and Parasitology, University College Hospital,  
17 Ibadan, Oyo State, Nigeria.

18 <sup>4</sup>Department of Medical Microbiology and Parasitology, Obafemi Awolowo University  
19 Teaching Hospitals Complex, Ile-Ife, Nigeria.

20 <sup>5</sup>Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences,  
21 College of Medicine, University of Lagos, Lagos, Nigeria

22 <sup>6</sup>Department of Medical Microbiology, School of Basic Clinical Sciences, Benjamin Carson  
23 College of Health and Medical Sciences, Babcock University & Teaching Hospital, Ilishan-  
24 Remo, Ogun State, Nigeria.

25 <sup>7</sup> Centre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford,

26 Oxford, United Kingdom.

27 <sup>8</sup> Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria.

28 ABSTRACT

29 **Background:** Salmonellosis causes significant morbidity and mortality in Africa. Despite  
30 being endemic in Nigeria, information on circulating lineages of invasive *Salmonella* is  
31 sparse.

32 **Methods:** *Salmonella enterica* isolated from blood (n=60) and cerebrospinal fluid (CSF,  
33 n=3) between 2016 and 2020 from five tertiary hospitals in southwest Nigeria were  
34 antimicrobial susceptibility-tested and Illumina-sequenced. Genomes were analysed using  
35 publicly-available bioinformatic tools.

36 **Results:** Isolates and sequence types (STs) from blood were *S. Typhi* [ST1, n =1 and ST2, n  
37 =43] and invasive non-typhoidal *Salmonella* (iNTS) (*S. Enteritidis* [ST11, n=7], *S. Durham*  
38 [ST10, n=2], *S. Rissen* [ST8756, n=2], *S. Chester* [ST2063, n=1], *S. Dublin* [ST10, n=1], *S.*  
39 *Infantis* [ST603, n=1], *S. Telelkebir* [ST8757, n=1] and *S. Typhimurium* [ST313, n=1], *S.*  
40 *Typhi* ST2 (n=2) and *S. Adabraka* ST8757 (n=1) were recovered from CSF. Most *S. Typhi*  
41 belonged to genotype 3.1.1 (n=44), carried an IncY plasmid and had several antibiotic  
42 resistance genes (ARGs) including *bla*<sub>TEM-1</sub> (n=38), *aph(6)-Id* (n=32), *tet(A)* (n=33), *sul2*  
43 (n=32), *dfrA14* (n=30) as well as quinolone resistance-conferring *gyrA\_S83Y* SNPs (n=37).  
44 All *S. Enteritidis* harboured *aph(3'')-Ib*, *bla*<sub>TEM-1</sub>, *catA1*, *dfrA7*, *sul1*, *sul2*, *tet(B)* genes, and  
45 a single ARG, *qnrB19*, was detected in *S. Telelkebir*. Typhoidal toxins *cdtB*, *pltA* and *pltB*  
46 were detected in *S. Typhi*, *Rissen*, *Chester*, and *Telelkebir*.

47 **Conclusion:** Most invasive salmonellosis in south west Nigeria are vaccine-preventable  
48 infections due to multidrug-resistant, West African dominant Typhi lineage 3.1.1.. Invasive  
49 NTS serovars, including some harbouring typhoidal toxin or resistance genes represented a  
50 third of the isolates emphasizing the need for better diagnosis and surveillance.

51

52

53

54 **Author Summary**

55 Whole genome sequencing of 63 invasive *Salmonella* from 5 tertiary hospitals in Nigeria  
56 revealed multiple serovars including a dominant antibiotic-resistance-gene harbouring *S.*  
57 Typhi 3.1.1 genotype comprising a *gyrA*\_S83Y and IncY plasmid. We also report invasive  
58 non-typhoidal *Salmonella* harbouring typhoidal toxins.

59

60

61 *INTRODUCTION*

62 *Salmonella* are a group of Gram negative, motile, facultative anaerobic rod-shaped bacteria  
63 belonging to the *Enterobacteriaceae* family. This genus consists of two known species,  
64 *Salmonella enterica* and *Salmonella bongori*. *S. enterica* are further distributed across six  
65 subspecies, of which the *S. enterica* subsp. *enterica* are most reported in infections involving  
66 homeotherm animals [1]. Furthermore, *S. enterica* subsp. *enterica* consists of over 1500  
67 serovars with distinct antigenic specificity [2]. The human host-adapted *S. enterica* subsp.  
68 *enterica* serovars are usually associated with three marked clinical syndromes: *Salmonella*  
69 *enterica* subsp. *enterica* serovar Typhi cause typhoid fever, and the non-typhoidal *Salmonella*  
70 (NTS) cause bacteraemia and gastroenteritis in immunocompromised (including persons with  
71 advanced HIV disease, cases of severe malaria and malnutrition in children) and  
72 immunocompetent persons, respectively [3,4]. *S. Paratyphi* A, B and C produce a syndrome  
73 similar to typhoid fever.

74 The public health impact of typhoidal and invasive non-typhoidal *Salmonella* infections is  
75 significant particularly in Africa and Asia where they have a great influence on morbidity and  
76 mortality [5,6]. For instance, an estimated 17.8 million cases of typhoid fever occur each year  
77 in low and middle-income countries (LMICs) [7]. An earlier estimate suggests that the  
78 burden of typhoid fever is >100 per 100000 individuals per annum in sub-Saharan Africa  
79 with an associated 1% mortality [8,9]. Furthermore, an estimated 26% (33,490 lives lost) of  
80 the annual global typhoid-related mortality is reported to occur in Africa [9]. The disease  
81 burden of typhoid in Nigeria is estimated at 364,791 typhoid cases resulting in 4,232 deaths  
82 (affecting 68% of individuals under 15 years of age) as at 2016 [10], however population-  
83 based data are only just becoming available [11]. Globally, NTS is estimated to cause  
84 approximately 94 million cases of gastroenteritis per annum worldwide with a resultant  
85 mortality of 155,000 [12]. In immunocompromised cases of the disease (amongst HIV-

86 positive adults), NTS is reported to cause a 20% case fatality (212,000 deaths) in sub-Saharan  
87 Africa (SSA) annually, while also being responsible for over 1 million cases of bloodstream  
88 infections in children in SSA with a case fatality of 18.1% (197,000 child mortality)  
89 [4,13,14].

90 Although available reports suggest infection with *Salmonella enterica* to be the most  
91 common cause of bloodstream infections in Africa [15], the incidence and microbiology of  
92 typhoidal and invasive non-typhoidal *Salmonella* (iNTS) is still poorly understood. Many  
93 regions on the continent have garnered little or no attention in the literature [7]. Blood  
94 culture-based surveillance represents the standard method for assessing the epidemiology and  
95 aetiology of bacterial invasive infections [16]. Limited surveillance of invasive *Salmonella* on  
96 the Africa continent is majorly due to financial, logistical, and infrastructural constraints for  
97 the institution and maintenance of blood culture-based surveillance systems in the region  
98 [7,8,16,17].

99 Such limitations not only obscure the true burden and prevalence of invasive *Salmonella*  
100 infections in resource-limited settings but also limit opportunity for genomic surveillance of  
101 this pathogen. For instance, despite the huge burden of typhoid infections in Nigeria, before  
102 the current study, there were only 131 *Salmonella* genomes (all *S. Typhi*) from the country on  
103 Pathogenwatch (<https://pathogen.watch/>, 15th November 2021) [18], a web-based platform  
104 for surveillance of microbial genomes all of which were collected on or before 2013, and  
105 most from only two centres [19]. Lack of genomic surveillance information of invasive  
106 *Salmonella* in resource-limited countries, including Nigeria, may deter interventions  
107 necessary to ameliorate this burden, such as the typhoid conjugate vaccines [8,17,19,20].  
108 Hence, this report provides genomic characterization of 2016-2020 invasive *Salmonella*  
109 retrieved from tertiary hospitals enrolled into Nigeria's Antimicrobial Surveillance Network  
110 coordinated by the Nigeria Centre for Disease Control (NCDC).

111

112

113 *MATERIALS AND METHODS*

114 **Ethical considerations**

115 Isolates were obtained as part of the surveillance efforts in line with Nigeria's national action  
116 plan. Ethical approval for using them in research was obtained from the University of  
117 Ibadan/University College Hospital ethics committee (UI/EC/15/093). Patient consent was  
118 not obtained and the data were analysed anonymously.

119

120 **Isolate collection, Identification and Antimicrobial Susceptibility Testing**

121 Tertiary hospitals located in southwest Nigeria and enrolled into the Nigeria Antimicrobial  
122 Surveillance Network provided cryopreserved isolates from blood and cerebrospinal fluid to  
123 the AMR National reference laboratory. The isolates were from retrospectively batched  
124 periods of 2016-2018 (retrospective isolates), 2019 and 2020. The national reference lab in  
125 partnership with the Global Health Research Unit for the Genomic Surveillance of  
126 Antimicrobial Resistance (GHRU-GSAR) conducted the re-identification of the isolates  
127 using the Gram-negative (GN) test kit on (Ref: 21341) on VITEK 2 systems (version 2.0,  
128 Marcy-l'Etoile, France, Biomérieux). Briefly, the cryopreserved isolates (at -80 °C) are  
129 resuscitated before use for reidentification by subculturing onto Salmonella-Shigella Agar  
130 and incubated aerobically at 37°C. Isolated colonies from pure cultures are the streaked on  
131 Nutrient Agar (NA), incubated aerobically at 37°C. Isolated colonies on NA is then used to  
132 prepare inoculum for VITEK using GN cards. This test is based on forty-seven biochemical  
133 tests and a negative control. The cards contain wells with substrates for the different tests in  
134 dried form. The cards are inoculated with a saline suspension of the organisms before  
135 incubation. Upon incubation, biochemical reactions are read by the machine and recorded as

136 positive or negative. A bionumber which is based upon the combination of different test  
137 results is then generated. The bionumber is compared to VITEK 2 robust database to match  
138 the organism and this is used to identify the organism. An added step for confirming identity  
139 of VITEK-identified isolates utilized whole-genome sequencing of all isolates. Antimicrobial  
140 susceptibility testing was done using VITEK AST N280 test kit (Ref: 413432). N280 Cards  
141 are incubated within the VITEK 2 compact upon inoculation with appropriate saline  
142 suspension of test organism. The minimum inhibitory concentration (MIC) is recorded as the  
143 highest concentration of an antibiotic for which no bacterial growth is observed. The MICs  
144 were interpreted as either resistant, intermediate or susceptible in accordance to CLSI  
145 standards [21].

146

#### 147 **DNA extraction and Library preparation**

148 The isolates were processed for the extraction of genomic DNA using Wizard DNA  
149 extraction kit (Promega; Wisconsin, USA) following manufacturer's instructions. The  
150 extracted DNA was quantified on a Qubit fluorometer (Invitrogen; California, USA) using  
151 dsDNA Broad Range quantification assay. Double-stranded DNA libraries were prepared  
152 using the Covaris LC220 for fragmentation, and NEBNext Ultra II FS DNA library kit for  
153 Illumina with 384-unique indexes (New England Biolabs, Massachusetts, USA; Cat. No:  
154 E6617L). Libraries were sequenced on an Illumina HiSeq X10 (Illumina, California, USA).

155

156

#### 157 **Genome Assembly**

158 Generated sequence reads from Illumina runs were *de novo* assembled following GHRU  
159 protocols (<https://gitlab.com/cgps/ghru/pipelines/dsl2/pipelines/assembly>) using a Nextflow  
160 workflow which inclusively comprises of adapter trimming (trimmomatic v0.38),



161 contamination detection (ConFindr v0.7.2), assembly (SPAdes v3.12.0), Quality Control  
162 (multiqc v1.7, qualifyr v1.4.4) and Bactinspector (v 0.1.3).

163

#### 164 **Sequence typing of *Salmonella* genomes**

165 Sequence reads were deposited in the *Salmonella* database on EnteroBase [22]. Multi-locus  
166 sequence types (MLST) for the isolates were determined and core-genome MLST calculated.  
167 Evolutionary relationship based on cgMLST of all *S. Typhi* of human origin from Africa  
168 deposited in Enterobase were determined [22]. The *Salmonella* genome assemblies were  
169 analysed using the *Salmonella* In-Silico Typing Resource (SISTR) for the prediction of  
170 serovars and serogroups ([https://github.com/phac-nml/sistr\\_cmd](https://github.com/phac-nml/sistr_cmd)). Genomes belonging to *S.*  
171 *Typhi* were loaded unto Pathogenwatch for the prediction of their genotypes [18].

172

#### 173 **Identification of AMR, Plasmids, Virulence genes and *Salmonella* Pathogenicity islands**

174 Determinants of AMR, virulence and plasmid replicons were identified following GHRU  
175 protocols (<https://gitlab.com/cgps/ghru/pipelines>). Prediction of *Salmonella* pathogenicity  
176 islands (SPIs) in the genomes was done by mapping raw reads to SPIs database  
177 ([https://bitbucket.org/genomicepidemiology/spifinder\\_db](https://bitbucket.org/genomicepidemiology/spifinder_db))

178

#### 179 **Single Nucleotide Polymorphism (SNP) calling and phylogeny**

180 The sequence reads of the *S. Typhi* and *S. Enteritidis* genomes from our study were mapped  
181 to NCBI reference sequence, *Salmonella enterica* subsp. *enterica* serovar *Typhi* strain  
182 H12ESR00755-001A (assembly accession: GCF\_001362195.2) and *Salmonella enterica*  
183 subsp. *enterica* serovar *Enteritidis* strain 18569 (assembly accession: GCF\_000335875.2),  
184 respectively, to determine evolutionary relationship amongst the strains following GHRU  
185 nextflow SNP phylogeny protocols ([https://gitlab.com/cgps/ghru/pipelines/snp\\_phylogeny](https://gitlab.com/cgps/ghru/pipelines/snp_phylogeny)).

186 Briefly, reads were trimmed (trimmomatic v0.38) and mapped to the reference genomes  
187 described above using bwa mem (v0.7.17) and variants were called and filtered using  
188 bcftools (v1.9). A pseudoalignment with the reference was used to generate a maximum  
189 likelihood tree using iqtree (v1.6.8) [23]. SNP distances between the genome pairs were  
190 calculated using snp-dists v.0.8.2 (<https://github.com/tseemann/snp-dists>) on the pseudo-  
191 genome alignment.

192

### 193 **Availability of sequence data**

194 Raw sequence data generated from this study are deposited in the European Nucleotide  
195 Archive under Bioproject PRJEB29739. Accession numbers for each genome is available in  
196 Supplementary Table 1.

197

## 198 *RESULTS*

### 199 **Invasive *Salmonella* from sentinel hospitals from Nigeria's AMR Surveillance Network**

200 Using the VITEK system for bacterial identification described above, a total of 69 isolates  
201 retrieved from patients from five (n=5) sentinel hospitals were identified as *Salmonella* spp.,  
202 at the reference laboratory. However, results from whole-genome sequencing confirmed n=61  
203 of these to be *Salmonella enterica*. In addition, two other isolates from our surveillance  
204 collection initially identified as *Escherichia coli* and *Acinetobacter baumannii* using VITEK  
205 were subsequently identified as *Salmonella enterica* using WGS.

206 The sixty-three (63) WGS-confirmed invasive *Salmonella* isolates have average number of  
207 contigs was 58 and N50 values ranged from 172132bp to 731013bp (average 246872 bp).  
208 The G+C (%) content of the genomes ranged from 51.86% - 52.37% (average 52.10%)  
209 (Supplementary Table 1). The isolates were retrieved from blood (n=60) and cerebrospinal  
210 fluid (n=3). The sending sentinel hospitals include: University of Ilorin Teaching Hospital

211 (ILO, Ilorin, Kwara State, n=25), University College Hospital, Ibadan (UCH, Ibadan, Oyo  
212 State, n=23), Obafemi Awolowo University Teaching Hospital, Ile-Ife (OAU, Ile-Ife, Osun  
213 State, n=8), Lagos University Teaching Hospital (LUT, Idi-Araba, Lagos State, n=4) and  
214 Babcock University Teaching Hospital (BUT, Ilishan-Remo, Ogun State, n=3) (Fig. 1A).  
215 Majority of the isolates were retrieved in 2019 from ILO (n=22). Thirteen isolates had no  
216 year specified metadata but were retrospective isolates retrieved between 2016 and 2018 (Fig  
217 1A). The hospitals are all in the southwestern part of Nigeria with ILO just north of the  
218 South-West geopolitical zone and all the rest within it. All the *Salmonella* isolates from  
219 cerebrospinal fluid were obtained from LUT.

220

#### 221 **Distribution of *Salmonella enterica* subsp. *enterica* serovars across sentinel hospitals**

222 All the *Salmonella enterica* isolates belonged to the subspecies *enterica* but differed by  
223 serotype with a total of 10 serovars detected. They include Typhi (n=46), Enteritidis (n=7),  
224 Durham (n=2), Rissen (n=2), Adabraka (n=1), Chester (n=1), Dublin (n=1), Infantis (n=1),  
225 Telelkebir (n=1), Typhimurium (n=1). Three *Salmonella enterica* isolates belonging to  
226 serovars Adabraka (n=1) and Typhi (n=2) were retrieved from cerebrospinal fluid from LUT.  
227 All other *Salmonella* serovars were retrieved by blood culture at the respective sentinel sites  
228 (Supplementary Table 1). *Salmonella* Typhi and iNTS were recovered from all sentinel sites,  
229 with iNTS being much less frequently recovered (Fig. 1B).

#### 230 **Sequence types, genotypes, and nucleotide polymorphisms.**

231 *Salmonella* sequence-typing based on Achtman's MLST scheme [24] identified two *S. Typhi*  
232 Sequence Types (STs) (ST1 = 1 and ST2 = 45). There were nine different iNTS STs. These  
233 included previously reported invasive STs: *S. Enteritidis* ST11 (n=7) and *S. Typhimurium*  
234 ST313 (n=1), which are repeatedly reported from Africa. Other iNTS were *S. Dublin* (ST10),  
235 *S. Infantis* (ST603), *S. Durham* (ST2010), *S. Chester* (ST2063), *S. Telelkebir* (ST2222). Two

236 novel STs belonging to *S. Rissen* and *S. Adabraka* were curated and designated STs 8756 and  
237 8757 respectively by EnteroBase.

238 To further place our *S. Typhi* genomes in a wider context, we performed cgMLST analysis  
239 based on differences in core genomes of our strains and all *S. Typhi* from human sources in  
240 Africa deposited in EnteroBase (n=980) (Fig 2). All genomes included in this study had  
241 similar core genome allelic differences at HC400, whereas at HC200 genomes from this  
242 study had similar allelic profile with 98.06% (n=961) of the genomes in the population.  
243 Genomes accounting for the difference in cluster numbers in the population at HC400 were  
244 from Nigeria (n=9, ~0.92%), Cameroon (n=4, ~0.41%) Algeria (n=3, ~0.3%) Morocco (n=2,  
245 0.2%) and Senegal (n=1, 0.1%). Generally, *S. Typhi* genomes from this study clustered with  
246 others from West Africa, including Nigeria, Cameroon, Togo, Mauritania, Mali, Burkina  
247 Faso, Guinea, Benin, and Ivory Coast, emphasizing further on their endemicity in the West  
248 Africa region (Fig 2).

249 Further, based on *S. Typhi* genotyping scheme, we observed that the isolate of *S. Typhi* ST1  
250 belonged to genotype 4.1 (UCH), whereas genotypes 2.3.1 (n=1, UCH) and 3.1.1 (n= 44)  
251 were *S. Typhi* ST2 isolates. In addition, *S. Typhi* genomes from CSF (n=2) belonged to the  
252 3.1.1 genotype. To further investigate the genetic relatedness of the genomes in this study, we  
253 report outcome of pairwise SNP differences among the genomes. Pairwise SNP difference  
254 ranged from 401 to 431 between *S. Typhi* 4.1 and other *S. Typhi* genotypes in this study,  
255 whereas it was 401 to 521 between *S. Typhi* 2.3.1 and other *S. Typhi* genotypes. The  
256 dominant Typhi genotype, *S. Typhi* 3.1.1 were 0 to 47 SNPs apart (Supplementary Table 3). .  
257 Among *S. Enteritidis*, pairwise SNP difference ranged from 0 to 44 in the three sentinel labs  
258 (UCH, OAU, ILO) where they were isolated. One pair of *S. Enteritidis* isolates from UCH  
259 were identical and the third isolate was 33 SNPs apart from them. The three *S. Enteritidis*

260 isolates from ILO (n=3) were near identical having pairwise SNP range from 0 to 1  
261 (Supplementary Table 4).

262

263 **Antimicrobial susceptibility profiles, antimicrobial resistance determinants and**  
264 **plasmids replicons in TS and NTS**

265 Antimicrobial susceptibility testing revealed majority of the *S. Typhi* to be resistant to  
266 sulphamethoxazole/trimethoprim (SXT) and ampicillin (n=41 each) and nalidixic acid  
267 (n=36), of which three were ciprofloxacin non-susceptible, according to CLSI (2021) criteria.  
268 (Supplementary Table 2). While not relevant to the antimicrobial chemotherapy of invasive  
269 infections, resistance to nitrofurantoin was identified in the n=2 *S. Typhi* isolated from CSF  
270 and in n=9 isolates from blood with the highest MICs (128 µg/mL) seen in the CSF isolates  
271 only. Resistance to cephalosporins, cefuroxime and cefuroxime axetil was observed in *S.*  
272 *Typhi* 3.1.1 from UCH.

273 The single *S. Typhi* 2.3.1 isolate was resistant to ampicillin and SXT whereas no phenotypic  
274 resistance was observed with *S. Typhi* 4.1. All *S. Enteritidis* and *S. Typhimurium* were  
275 resistant to ampicillin and sulphamethoxazole/trimethoprim. Besides Telelkebir harbouring  
276 resistance to nalidixic acid and ciprofloxacin, other NTS were either susceptible or  
277 intermediately resistant to other antimicrobials (Supplementary Table 2). For example, *S.*  
278 *Adabraka*, *Dublin* and *Telelkebir* were intermediately resistant to cefuroxime axetil.  
279 (Supplemental Table 2 and microreact link for antimicrobial susceptibility testing:  
280 [https://microreact.org/project/ahQ3Yb64nsbnhHMzz3WQn9-genomic-epidemiology-of-](https://microreact.org/project/ahQ3Yb64nsbnhHMzz3WQn9-genomic-epidemiology-of-invasive-salmonella-in-southwestern-nigeria-ast-data)  
281 [invasive-salmonella-in-southwestern-nigeria-ast-data](https://microreact.org/project/ahQ3Yb64nsbnhHMzz3WQn9-genomic-epidemiology-of-invasive-salmonella-in-southwestern-nigeria-ast-data))

282

283 A combined total of 14 acquired antimicrobial resistance genes (ARGs) conferring resistance  
284 to drugs within seven antibiotic classes were detected amongst the genomes. Amongst the *S.*

285 Typhi genomes, n=36/46 harboured at least one ARG conferring reduced susceptibility to 5  
286 antibiotic classes, with n=41 harbouring a sulphonamide resistance gene [*sul1* =9/46, *sul2* =  
287 33/46]) and n=39 each harbouring a beta-lactam (*bla*<sub>TEM-1</sub>), tetracyclines (*tetA*, n=33 and *tetB*,  
288 n=6), and trimethoprim resistance determinant (*dfrA1*, [n=1], *dfrA15* [n=8] and *dfrA14*  
289 [n=30]). In addition, chloramphenicol resistance genes, *catA1*, were also detected in the  
290 genomes (n=8). Point mutations identified among the sequenced *S. Typhi* isolates were those  
291 associated with the quinolone resistance determining region (QRDR), *gyrA*\_S83Y SNPs  
292 (n=37), which mediate resistance to fluoroquinolones (Fig 3). Furthermore, n=45 of the *S.*  
293 *Typhi* genomes had at least one plasmid predicted to occur in each genome. Majority (n=33)  
294 possessed an IncY plasmid replicon, plasmid replicons IncFIA\_HI1, IncHIA and IncHIB  
295 were respectively detected in n=9 of *S. Typhi* genomes whereas one isolate harboured an  
296 IncQ plasmid replicon (Fig 3).

297

298 For the iNTS, *S. Enteritidis* genomes possessed at least one ARG to six antibiotic classes. All  
299 isolates of this serotype harboured *aph(3'')-Ib*, *bla*<sub>TEM-1</sub>, *catA1*, *dfrA7*, *sul1*, *sul2*, *tet(B)*  
300 genes, and only differed in the absence/presence of *aph(6)-Id* (n=4) (Fig 4). In tandem, *S.*  
301 *Typhimurium* harbour ARGs [*aadA1*, *aph(3'')-Ib*, *aph(6)-Id*, *bla*<sub>TEM-1</sub>, *catA1*, *dfrA1*, *sul1*,  
302 *sul2*] encoding resistance to 5 antibiotic classes (Fig 5). The only occurring quinolone  
303 resistance gene among isolates in this study, *qnrB19*, was detected in *S. Telelkebir*. No ARGs  
304 were detected in *Salmonella* serovars Chester, Rissen, Durham, Infantis, Adabraka and  
305 Dublin. Antimicrobial point mutations identified among iNTS were associated with *gyrA* and  
306 *parC* gene regions (Fig 5). The quinolone resistance conferring *gyrA*\_D87Y SNPs were  
307 identified only amongst *S. Enteritidis* (ILO, n = 3 and UCH, n = 1), whereas the *parC*\_T57S  
308 mutations were detected in all iNTS except *S. Enteritidis* and *S. Typhimurium*. Plasmids

309 were predicted to occur only in *S. Dublin* [IncFII(S), IncX1 and IncX1\_1], *S. Enteritidis*  
310 (IncI1 and IncQ1), *S. Typhimurium* [IncFIB, IncFII(S) and IncQ1] among the iNTS.

311

### 312 **Predominant IncY + gyrA\_S83Y + tetA harbouring *S. Typhi* 3.1.1 in Nigeria**

313 We observe that all *S. Typhi* of the 3.1.1 lineage harbouring an IncY plasmid replicon  
314 (n=33/46) similarly possessed the gyrA\_S83Y chromosomal gene mutation and harboured a  
315 *tetA* gene. Although other antimicrobial resistance genes were seen at slightly lower numbers  
316 (n= 32/33 for *sul2* and *aph(6)*-Id and n=30/33 for *bla*<sub>TEM-1</sub> and *dfrA14*), the  
317 IncY+gyrA\_S83Y+tetA in *S. Typhi* 3.1.1 phenomenon was observed to occur in all the  
318 sentinel hospitals in this study. Additionally, maximum pairwise SNP distance between the  
319 variants in this cluster was 23. This is approximately twice as less of what was determined in  
320 *S. Typhi* 3.1.1 outside this cluster (n=47), thereby, emphasizing clonality within this cluster.

321

### 322 ***Salmonella* virulence determinants and predicted pathogenicity islands**

323 The isolates possessed a plethora of virulence determinants (Supplementary Table 2). Among  
324 the *S. Typhi* genomes, a total of 98 virulence determinants were detected, and 97 of these  
325 were conserved within members of this serovar (with the exception of *pipB2* gene in an *S.*  
326 *Typhi* 3.1.1 from UCH).

327 A total of 106 virulence genes were detected among the *S. Enteritidis* genomes, 104 of these  
328 were conserved within these genomes, with 2 strains from UCH lacking either a *Salmonella*  
329 secreted protein H (*sppH*) or secretion system effector I (*sseI*). A total of 122 virulence genes  
330 were detected in the iNTS genomes, and n=86 of these were conserved in all iNTS genomes.  
331 For instance, the iNTS possessed genes encoding (i) Adherence; such as *agf* – thin  
332 aggregative fimbriae or curli (*csgABCDEGF*), *misl* – an autotransporter protein, *pef* - plasmid-  
333 encoded fimbriae (present only in *S. Typhimurium*) *ratB* (carried by iNTS strains harbouring

334 CS54 islands), *shdA* (only found in *S. Infantis*), *sinH* (detected in all NTS except *S.*  
335 Enteritidis) and Type 1 fimbriae (*fimCDFHI*) (ii) Stress adaptation; *sodCI* – superoxide  
336 dismutase (detected in iNTS serovars except Durham, Chester and Rissen and Infantis and  
337 Telelkebir), *sopA* (not detected in *S. Infantis*) (iii) Nutritional/metabolic factor (*mgtBC*,  
338 present in all strains) (iii) Antimicrobial activity/competitive advantage; such as macrophage  
339 inducible genes (*mig-14*, present in all strains) and (iv) Enterotoxin; T3SS effectors – *spvBC*  
340 (in *S. Typhimurium*, Enteritidis and Dublin), *avrA* (in all iNTS except *S. Dublin*) and  
341 Typhoidal toxin - *cdtB* (present in *S. Durham*, *S. Telelkebir* and *S. Chester*).

342 Since the *cdtB* are reported to be co-located with other cytolethal distending toxins (*cdt*),  
343 pertussis-like toxins A (*pltA*) and B (*pltB*), on same pathogenicity islet [25], we ran a blast  
344 search of our strains for the presence of *pltA* and *pltB*. The nucleotide sequences were  
345 extracted from the virulence factor database (VFDB) and used as a local database for a blast  
346 search against our iNTS genomes. Our results reveal high similarity (100% coverage and  $\geq$   
347 96.62% identity) with *cdtB*, *pltA* and *pltB* genes in the iNTS genomes (*S. Chester*, *S. Durham*  
348 and *S. Telelkebir*).

349

350 Eleven and twelve *Salmonella* pathogenicity islands (SPIs) were predicted in *S. Typhi* and  
351 iNTS genomes, respectively (Fig 6). All *S. Typhi* were predicted to have 10 SPIs, i.e., SPI-1,  
352 SPI-2, SPI-3, SPI-4, SPI-5, SPI-6, SPI-7, SPI-8, SPI-9, SPI-10 and SPI-12. However, SPI-4  
353 was predicted to occur only in *S. Typhi* lineages 2.3.1 and 4.1. In contrast to *S. Typhi*, only  
354 SPI-3 was predicted to occur in all the iNTS genomes. Certain SPIs were shown to be  
355 associated with members of certain serovars. For instance, SPI-2 and SPI-8 were detected  
356 only in *S. Typhimurium* and *S. Rissen*, respectively. Other pathogenicity islands were  
357 detected in this study (Fig 3), such as SPI-4 (*S. Adabraka*, Chester, Typhimurium), SPI-6 (all  
358 NTS except *S. Durham*, Rissen and Telelkebir), SPI-12 (all NTS except *S. Chester*, Durham,



359 Rissen and Telelkebir) and CS54\_island was detected in *S. Dublin*, *S. Typhimurium*, *S.*  
360 *Infantis* and *S. Enteritidis* (n=6).

361

## 362 *DISCUSSION*

363 In this report we present the outcome of genomic characterization of invasive *Salmonella*  
364 infections from AMR surveillance in sentinel hospitals in Nigeria. The genomic  
365 characterization of invasive *Salmonella* isolates in this study was possible because these  
366 hospitals perform blood culture and are enrolled in Nigeria's new antimicrobial resistance  
367 surveillance system, which offers genomic services at the National Reference Laboratory  
368 level [26]. Nonetheless, blood culture is available at very few institutions in Nigeria, a  
369 limitation still prevalent in many African settings that impacts the genomic surveillance of  
370 invasive *Salmonella*. [8,16,27]. Moreover, these sentinels perform very few blood cultures so  
371 that the isolates studied here represent a very small proportion of circulating strains.

372

373 Using high-throughput WGS and bioinformatic analytics, we were able to determine  
374 prevalent serotypes and dominant genotypes of invasive *Salmonella* infections. Most of the  
375 *Salmonella* isolates cultured from blood were *S. Typhi*, as has been previously reported from  
376 different parts of Nigeria, including Ibadan [28–30], even though iNTS may predominate in  
377 some other African settings [3,31]. While our data are few, the predominance of Typhi at all  
378 sites points to a significant burden of severe disease that could be averted if Typhoid  
379 Conjugate Vaccines were deployed in Nigeria. Out of a total of 10 *S. Typhi* genotypes  
380 recorded from Nigeria in Pathogenwatch, three were identified in this study. The *S. Typhi*  
381 genotype 3.1.1 we report was similarly common in the Nigeria cluster on Pathogenwatch  
382 (n=87/131). As in our study, this cluster possessed similar prevalence of genetic determinants  
383 of beta-lactam (*bla*<sub>TEM-1</sub> – 83.90%) resistance, indicating that these determinants are well-

384 conserved in the genotype. However, prevalence of other AMR genetic determinants from  
385 this lineage such as *catA1*, *sul1*, *sul2*, *dfrA14*, *dfrA15*, *tetA*, *tetB* were similar with what is  
386 reported from this study, but at different rates.

387 This multidrug-resistance gene-encoding *S. Typhi* 3.1.1 is shown to be one of the broadest  
388 lineages in sub-Saharan Africa and endemic in the West Africa region [19,32,33]. This *S.*  
389 *Typhi* genotype is frequently reported to multidrug and ciprofloxacin resistant [29,31]. All *S.*  
390 *Typhi* 3.1.1 (except one from OAU) harbouring quinolone-conferring SNPs in *gyrA* showed  
391 phenotypic resistance to nalidixic acid. Additionally, we observed that the *S. Typhi* genotype  
392 3.1.1 clone variants harboured an *IncY* + *gyrA\_S83Y* + *tetA* genes. The Pathogenwatch  
393 database includes three *S. Typhi* 3.1.1 strains isolated from blood samples in 2013, in Abuja,  
394 north-central capital of Nigeria with similar clonal characteristics (having same genotype,  
395 plasmid replicon, chromosomal QRDR and antimicrobial resistance gene, *tetA*) [19]. Outside  
396 Nigeria, this lineage has also been identified in the United Kingdom (accession:  
397 SRR7165434, SRR5585020) [32]. Our data suggest that this resistant sub-lineage is  
398 predominant in our setting and should be sought elsewhere in Nigeria and the region. In  
399 addition, long read sequencing to unveil the carriage of the *IncY* plasmids would be  
400 potentially vital to understanding the success of this lineage in Nigeria.

401

402 *S. Enteritidis* were the most frequently recovered iNTS in our study and sent from three  
403 sentinel hospitals. This outcome contrasts with earlier reports of *S. Typhimurium* ST313 as a  
404 predominant serotype in eastern and southern Africa, but also present across the continent,  
405 including Nigeria [15,34,35], but it is concordant with more recent reports describing *S.*  
406 *Enteritidis* in higher proportions in invasive infections in The Gambia [36]. Several of the *S.*  
407 *Enteritidis* in our study were multidrug resistant (resistant to ampicillin, SXT, nalidixic acid).  
408 This multidrug resistant clone has also been reported in bacteraemia in other parts of Africa

409 [37,38]. We observed that *S. Enteritidis* retrieved from different patients in ILO (in 2019) had  
410 highly similar genetic features (antimicrobial resistance determinants, virulence, plasmids  
411 replicons) and clustered together at 0-1 SNP distances between them. The isolates were  
412 recovered on the 27<sup>th</sup> of June, 26<sup>th</sup> of August and 28<sup>th</sup> of August 2019 and their genetic,  
413 geographic and temporal connectedness may be indicative of a previously unrecognized  
414 outbreak. Both *S. Typhimurium* ST313 and *S. Enteritidis* ST11 are dominant, human-adapted  
415 clones in sub-Saharan Africa [38] and are a major cause of invasive disease, with a  
416 corresponding high case-fatality rate [14]. These serovars are justifiably vaccine development  
417 priorities. Non typhoidal *Salmonella* serovars, such as Dublin, Infantis, Chester, Rissen have  
418 been reported severally from food animals [39–43], their presence in human invasive human  
419 infection may attest to concerns with water and food safety, including animal contact [44–  
420 46]. Although no ARGs were detected in this genome of these serovars, they remain a public  
421 health concern [46,47]. The single occurrence of an acquired quinolone resistance gene,  
422 *qnrB19* in this study was detected in *S. Telelkebir*. The strain also harboured phenotypic  
423 resistance to the quinolone, nalidixic acid and ciprofloxacin. *S. Telelkebir* has been reported a  
424 few times in Africa (as seen in Enterobase, [48]), and are more commonly reported in parts of  
425 Europe, China and USA [49]. The expansion of atypical *Salmonella* serovars in invasive  
426 infections is associated with a high health burden [17,36]. Invasive NTS vaccines in the  
427 pipeline may not cover all NTS serovars [50], and we identified several in this study,  
428 harbouring an assortment of virulence and antimicrobial resistance determinants. This points  
429 to the need for widespread and robust access to invasive *Salmonella* diagnostics in Nigeria to  
430 elucidate on the burden and make a case for serovar vaccine priorities [17,36,49].[49][17,36]  
431  
432 Amongst a plethora of virulence determinants present on both *S. Typhi* and iNTS, we  
433 observed that *S. Telelkebir*, *S. Durham* and *S. Chester* isolates harboured the cytolethal

434 distending toxin islet genes (*cdtB*, *pltA*, *pltB*) also known as typhoid toxin. These toxins were  
435 originally thought to be restricted to serovars Typhi and Paratyphi A [51]. However, these  
436 have now been reported in other NTS serovars including Bredeney, Javiana, Montevideo,  
437 Schwarzengrund, and more recently in Teitelkebir [52–54]. A literature search on PubMed  
438 and Google Scholar revealed little information on these toxins being reported in *S. Durham*  
439 and *S. Chester*. The cytolethal distending toxin islet cause DNA damage and cell cycle arrest  
440 in impaired cells [55]. More implicatively, these genes encoded by NTS serovars have been  
441 reported to play vital roles in disease pathogenesis [53,54]. Many of *Salmonella* virulence  
442 determinants are clustered in pathogenicity island on the bacterial chromosome, playing key  
443 roles in disease pathogenesis [56,57]. A variety of SPIs were identified in this study. The SPI-  
444 7 which were exclusively detected in *S. Typhi* in this study are known to be large and major  
445 backbone constituent of *S. Typhi*, harbouring several virulence determinants including the Vi  
446 antigen [58]. Like in this study, the CS54 island and SPI-14 island are more commonly  
447 detected NTS [59–62], with scarce reports in *S. Typhi*, and the CS54 island are suggested to  
448 have evolved over multiple horizontal transfers [63]. Thus, this study emphasizes on an  
449 expanding number of serovars causing invasive infections in the country, and the public  
450 health implications therein. Further studies focussed on molecular analysis of gene content of  
451 SPIs in invasive *Salmonella* infections could be pertinent in understanding pathogenesis and  
452 aid in the advancement of treatment options [64].

453

#### 454 *CONCLUSION*

455 The outcome of our study emphasizes the need for expanded genomic surveillance of  
456 invasive *Salmonella* infections in Nigeria as a valuable tool to monitor antibiotic resistance  
457 spread and genetic characterization of circulating lineages in Nigeria. Close monitoring of the  
458 dominant *S. Typhi* 3.1.1 clone harbouring the IncY plasmid replicon and *gyrA*\_S83Y

459 chromosomal mutation, identified in all the tertiary hospitals in this study, including other  
460 serovars is vital, and this may help to establish strategies for empirical treatment and control  
461 of spread of antibiotic resistant lineages. Furthermore, our data suggests that introducing  
462 typhoid conjugate vaccines, recommended by the World Health Organization for countries  
463 like Nigeria that have a high typhoid disease burden, will have a significant impact on health  
464 [65]. Development of vaccines which target NTS would be useful in reducing the overall  
465 burden of NTS on the continent. Rigorous surveillance plays an essential part in determining  
466 which serovars most require coverage, as we observe *S. Enteritidis* to be most prevalent NTS  
467 in invasive infections in southwest Nigeria, and hence recommended as vaccine priorities.  
468 Importantly, broader protective effects may be achieved by improvements in water, sanitation  
469 and hygiene that could interrupt transmission of the causes of typhoid and other invasive  
470 salmonellosis.

471

#### 472 *FUNDING*

473 This work was supported by Official Development Assistance (ODA) funding from the  
474 National Institute of Health Research <https://www.nihr.ac.uk/> (grant number 16\_136\_111) to  
475 DMA and INO and the Wellcome Trust <https://wellcome.org/> grant number 206194 to DMA.  
476 INO was an African Research Leader supported by the UK Medical Research Council  
477 (MRC) <https://mrc.ukri.org/> and the UK Department for International Development (DFID)  
478 under the MRC/DFID Concordat agreement that is also part of the EDCTP2 program  
479 supported by the European Union (Award # MR/L00464X/1) and is presently a Calestous  
480 Juma Science Leadership Fellow supported by the Bill and Melinda Gates Foundation  
481 <https://www.gatesfoundation.org/> (Award # INV-036234). The funders had no role in study  
482 design, data collection and analysis, decision to publish, or preparation of the manuscript.

483

484 *ACKNOWLEDGEMENT*

485 We thank Chinenye Ekemezie, Ifeoluwa J. Akintayo, Dorothy U Cyril-Okoh, Abeebe A.  
486 Adeniyi and Ifeanyi E. Mba for excellent technical contributions and Jola-Ade J. Ajiboye for  
487 logistic assistance. We are grateful to the administration and staff of the five sentinels for  
488 supporting them in surveillance.

489

490

491

492

493

494

495 *REFERENCES*

- 496 1. Giner-Lamia J, Vinuesa P, Betancor L, Silva C, Bisio J, Soletto L, Chabalgoity JA,  
497 Puente JL, Soncini FC, García-Vescovi E, Flores G, Pedraza J, Yim L, García C,  
498 Astocondor L, Ochoa T, Hinostroza N, Graciela Pucciarelli M, Hernández-Alvarez A,  
499 Del Moral V, García-Del Portillo F. Genome analysis of *Salmonella enterica* subsp.  
500 *diarizonae* isolates from invasive human infections reveals enrichment of virulence-  
501 related functions in lineage ST1256. *BMC Genomics*. 2019 Jan 31;20(1):1–14.
- 502 2. Issenhuth-Jeanjean S, Roggentin P, Mikoleit M, Guibourdenche M, De Pinna E, Nair  
503 S, Fields PI, Weill FX. Supplement 2008–2010 (no. 48) to the White–Kauffmann–Le  
504 Minor scheme. *Research in Microbiology*. 2014 Sep 1;165(7):526–30.
- 505 3. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-  
506 typhoidal salmonella disease: an emerging and neglected tropical disease in Africa.  
507 *The Lancet*. 2012 Jun 30;379(9835):2489–99.
- 508 4. Keestra-Gounder AM, Tsois RM, Bäumlér AJ. Now you see me, now you don't: the  
509 interaction of *Salmonella* with innate immune receptors. *Nature Reviews Microbiology*  
510 2015 13:4. 2015 Mar 9;13(4):206–16.
- 511 5. Smith SI, Seriki A, Ajayi A. Typhoidal and non-typhoidal *Salmonella* infections in  
512 Africa. Vol. 35, *European Journal of Clinical Microbiology and Infectious Diseases*.  
513 2016. p. 1913–22.
- 514 6. Phu Huong Lan N, Le Thi Phuong T, Nguyen Huu H, Thuy L, Mather AE, Park SE,  
515 Marks F, Thwaites GE, Van Vinh Chau N, Thompson CN, Baker S. Invasive Non-  
516 typhoidal *Salmonella* Infections in Asia: Clinical Observations, Disease Outcome and  
517 Dominant Serovars from an Infectious Disease Hospital in Vietnam. *PLoS Neglected*  
518 *Tropical Diseases*. 2016 Aug 11;10(8):e0004857.
- 519 7. Antillón M, Warren JL, Crawford FW, Weinberger DM, Kürüm E, Pak GD, Marks F,  
520 Pitzer VE. The burden of typhoid fever in low- and middle-income countries: A meta-

- 521 regression approach. *PLOS Neglected Tropical Diseases*. 2017 Feb  
522 27;11(2):e0005376.
- 523 8. Crump JA, Heyderman RS. A Perspective on Invasive Salmonella Disease in Africa.  
524 *Clinical Infectious Diseases*. 2015 Nov 1;61(suppl\_4):S235–40.
- 525 9. Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale V V., Ramani E, Kim YE, Park  
526 JK, Wierzba TF. Burden of typhoid fever in low-income and middle-income countries:  
527 a systematic, literature-based update with risk-factor adjustment. *The Lancet Global*  
528 *Health*. 2014 Oct 1;2(10):e570–80.
- 529 10. TyVAC. Potential of typhoid conjugate vaccines in Nigeria. 2017. 2017 Nov.
- 530 11. Park SE, Toy T, Cruz Espinoza LM, Panzner U, Mogeni OD, Im J, Poudyal N, Pak  
531 GD, Seo H, Chon Y, Schütt-Gerowitz H, Mogasale V, Ramani E, Dey A, Park JY, Kim  
532 JH, Seo HJ, Jeon HJ, Haselbeck A, Conway Roy K, MacWright W, Adu-Sarkodie Y,  
533 Owusu-Dabo E, Osei I, Owusu M, Rakotozandrindrainy R, Soura AB, Kabore LP,  
534 Teferi M, Okeke IN, Kehinde A, Popoola O, Jacobs J, Lunguya Metila O, Meyer CG,  
535 Crump JA, Elias S, MacLennan CA, Parry CM, Baker S, Mintz ED, Breiman RF,  
536 Clemens JD, Marks F. The Severe Typhoid Fever in Africa Program: Study Design  
537 and Methodology to Assess Disease Severity, Host Immunity, and Carriage Associated  
538 with Invasive Salmonellosis. *Clinical Infectious Diseases*. 2019 Oct  
539 30;69(Supplement\_6):S422–34.
- 540 12. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, Jones TF, Fazil A,  
541 Hoekstra RM. The global burden of nontyphoidal salmonella gastroenteritis. *Clinical*  
542 *Infectious Diseases*. 2010 Mar 15;50(6):882–9.
- 543 13. Gordon MA. Salmonella infections in immunocompromised adults. *Journal of*  
544 *Infection*. 2008 Jun 1;56(6):413–22.
- 545 14. Reddy EA, Shaw A V., Crump JA. Community-acquired bloodstream infections in  
546 Africa: a systematic review and meta-analysis. *The Lancet Infectious Diseases*. 2010  
547 Jun 1;10(6):417–32.
- 548 15. Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A Systematic Review  
549 and Meta-analysis of the Prevalence of Community-Onset Bloodstream Infections  
550 among Hospitalized Patients in Africa and Asia. 2019;
- 551 16. Ombelet S, Barbé B, Affolabi D, Ronat JB, Lompo P, Lunguya O, Jacobs J, Hardy L.  
552 Best Practices of Blood Cultures in Low- and Middle-Income Countries. *Frontiers in*  
553 *Medicine*. 2019 Jun 18;6.
- 554 17. Balasubramanian R, Im J, Lee JS, Jeon HJ, Mogeni OD, Kim JH, Rakotozandrindrainy  
555 R, Baker S, Marks F. The global burden and epidemiology of invasive non-typhoidal  
556 Salmonella infections. <https://doi.org/101080/2164551520181504717>. 2018 Jun  
557 3;15(6):1421–6.
- 558 18. Argimón S, Yeats CA, Goater RJ, Abudahab K, Taylor B, Underwood A, Sánchez-  
559 Busó L, Wong VK, Dyson ZA, Nair S, Park SE, Marks F, Page AJ, Keane JA, Baker  
560 S, Holt KE, Dougan G, Aanensen DM. A global resource for genomic predictions of  
561 antimicrobial resistance and surveillance of Salmonella Typhi at pathogenwatch.  
562 *Nature Communications* 2021 12:1 [Internet]. 2021 May 17 [cited 2021 Nov  
563 13];12(1):1–12. Available from: <https://www.nature.com/articles/s41467-021-23091-2>
- 564 19. Wong VK, Holt KE, Okoro C, Baker S, Pickard D, Marks F, Page AJ, Olanipekun G,  
565 Munir H, Alter R, Fey PD, Feasey NA, Weill FX, le Hello S, Hart PJ, Kariuki S,  
566 Breiman RF, Gordon MA, Heyderman RS, Jacobs J, Lunguya O, Msefula C,  
567 MacLennan CA, Keddy KH, Smith AM, Onsare RS, de Pinna E, Nair S, Amos B,  
568 Dougan G, Obaro S, Parkhill J, Kingsley RA, Thomson NR, Keane JA, Hawkey J,  
569 Edwards DJ, Dyson ZA, Harris SR, Cain AK, Hadfield J, Klemm EJ, Watson CH,  
570 John Edmunds W, Chabalgoity JA, Kama M, Jenkins K, Dutta S, Campos J,



- 571 Thompson C, Dolecek C, Parry CM, Karkey A, Kim Mulholland E, Campbell JI,  
572 Dongol S, Basnyat B, Arjyal A, Dufour M, Bandaranayake D, Toleafoa TN, Pravin  
573 Singh S, Hatta M, Isaia L, Thwaites G, Turner P, Soeng S, Crump JA, Nille EJ, Thanh  
574 DP, Valcanis M, Powling J, Dimovski K, Hogg G, Connor TR, Dave J, Murphy N,  
575 Holliman R, Sefton A, Millar M, Farrar J, Mather AE. Molecular Surveillance  
576 Identifies Multiple Transmissions of Typhoid in West Africa. *PLoS Negl Trop Dis*  
577 [Internet]. 2016 Sep 22 [cited 2022 May 2];10(9). Available from:  
578 <https://pubmed.ncbi.nlm.nih.gov/27657909/>
- 579 20. Carey ME, Steele AD. The Severe Typhoid Fever in Africa Program Highlights the  
580 Need for Broad Deployment of Typhoid Conjugate Vaccines. *Clinical Infectious*  
581 *Diseases*. 2019 Oct 30;69(Supplement\_6):S413–6.
- 582 21. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for  
583 Antimicrobial Susceptibility Testing. 2021, 31st ed, CLSI supplement M100.
- 584 22. Zhou Z, Alikhan NF, Mohamed K, Fan Y, Group the AS, Achtman M, Brown D,  
585 Chattaway M, Dallman T, Delahay R, Kornschober C, Pietzka A, Malorny B,  
586 Petrovska L, Davies R, Robertson A, Tyne W, Weill FX, Accou-Demartin M,  
587 Williams N. The EnteroBase user’s guide, with case studies on Salmonella  
588 transmissions, *Yersinia pestis* phylogeny, and *Escherichia core* genomic diversity.  
589 *Genome Research* [Internet]. 2020 Jan 1 [cited 2021 Nov 13];30(1):138–52. Available  
590 from: <https://genome.cshlp.org/content/30/1/138.full>
- 591 23. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: A Fast and Effective  
592 Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. *Molecular*  
593 *Biology and Evolution* [Internet]. 2015 Jan 1 [cited 2022 Apr 30];32(1):268–74.  
594 Available from: <https://academic.oup.com/mbe/article/32/1/268/2925592>
- 595 24. Achtman M, Wain J, Weill FX, Nair S, Zhou Z, Sangal V, Krauland MG, Hale JL,  
596 Harbottle H, Uesbeck A, Dougan G, Harrison LH, Brisse S. Multilocus Sequence  
597 Typing as a Replacement for Serotyping in *Salmonella enterica*. *PLOS Pathogens*.  
598 2012;8(6):e1002776.
- 599 25. Simon NC, Aktories K, Barbieri JT. Novel bacterial ADP-ribosylating toxins: structure  
600 and function. *Nat Rev Microbiol* [Internet]. 2014 [cited 2021 Nov 20];12(9):599.  
601 Available from: [/pmc/articles/PMC5846498/](https://pubmed.ncbi.nlm.nih.gov/25846498/)
- 602 26. Afolayan AO, Oaikhena AO, Aboderin AO, Olabisi OF, Amupitan AA, Abiri O v,  
603 Ogunleye VO, Odih EE, Adeyemo AT, Adeyemo AT, Obadare TO, Abrudan M,  
604 Argimón S, David S, Kekre M, Underwood A, Egwuenu A, Ihekweazu C, Aanensen  
605 DM, Okeke IN, Abudahab K, Harste H, Muddyman D, Taylor B, Wheeler N, Donado-  
606 Godoy P, Fabian Bernal J, Arevalo A, Fernanda Valencia M, Osma Castro ECD,  
607 Ravikumar KL, Nagaraj G, Shamanna V, Govindan V, Prabhu A, Sravani D, Shincy  
608 MR, Rose S, Ravishankar KN, Ajiboye JJ, Carlos C, Lagrada ML, Macaranas PK v,  
609 Olorosa AM, Gayeta JM, Herrera EM, Molloy A, Stelling J, Vegvari C. Clones and  
610 Clusters of Antimicrobial-Resistant *Klebsiella* From Southwestern Nigeria. *Clinical*  
611 *Infectious Diseases*. 2021;73(Supplement\_4):S308–15.
- 612 27. Petti CA, Polage CR, Quinn TC, Ronald AR, Sande MA. Laboratory medicine in  
613 Africa: A barrier to effective health care. *Clinical Infectious Diseases*. 2006 Feb  
614 1;42(3):377–82.
- 615 28. Obaro SK, Hassan-Hanga F, Olateju EK, Umoru D, Lawson L, Olanipekun G, Ibrahim  
616 S, Munir H, Ihesiolor G, Maduekwe A, Ohiaeri C, Adetola A, Shetima D, Jibir BW,  
617 Nakaura H, Kocmich N, Ajose T, Idiong D, Masokano K, Ifabiyi A, Ihebuzor N, Chen  
618 B, Meza J, Akindele A, Rezac-Elgohary A, Olaosebikan R, Suwaid S, Gambo M, Alter  
619 R, Davies HD, Fey PD. *Salmonella* Bacteremia Among Children in Central and



- 620 Northwest Nigeria, 2008–2015. *Clinical Infectious Diseases*. 2015 Nov  
621 1;61(suppl\_4):S325–31.
- 622 29. Popoola O, Kehinde A, Ogunleye V, Adewusi OJ, Toy T, Mogeni OD, Aroyewun EO,  
623 Agbi S, Adekanmbi O, Adepoju A, Muyibi S, Adebisi I, Elaturoti OO, Nwimo C,  
624 Adeoti H, Omotosho T, Akinlabi OC, Adegoke PA, Adeyanju OA, Panzner U, Baker  
625 S, Park SE, Marks F, Okeke IN. Bacteremia Among Febrile Patients Attending  
626 Selected Healthcare Facilities in Ibadan, Nigeria. *Clinical Infectious Diseases*. 2019  
627 Oct 30;69(Supplement\_6):S466–73.
- 628 30. Akinyemi KO, Ajoseh SO, Fakorede CO. A systemic review of literatures on human  
629 *Salmonella enterica* serovars in Nigeria (1999-2018). *The Journal of Infection in*  
630 *Developing Countries* [Internet]. 2021 Sep 30 [cited 2022 May 19];15(09):1222–35.  
631 Available from: <https://jidc.org/index.php/journal/article/view/12186>
- 632 31. Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. Global burden of  
633 invasive nontyphoidal *Salmonella* disease, 2010(1). *Emerg Infect Dis*. 2015 Jun  
634 1;21(6):941–9.
- 635 32. Park SE, Pham DT, Boinett C, Wong VK, Pak GD, Panzner U, Espinoza LMC, von  
636 Kalckreuth V, Im J, Schütt-Gerowitt H, Crump JA, Breiman RF, Adu-Sarkodie Y,  
637 Owusu-Dabo E, Rakotozandrindrainy R, Soura AB, Aseffa A, Gasmelseed N, Keddy  
638 KH, May J, Sow AG, Aaby P, Biggs HM, Hertz JT, Montgomery JM, Cosmas L,  
639 Olack B, Fields B, Sarpong N, Razafindrabe TJL, Raminosoa TM, Kabore LP, Sampo  
640 E, Teferi M, Yeshitela B, el Tayeb MA, Sooka A, Meyer CG, Krumkamp R, Dekker  
641 DM, Jaeger A, Poppert S, Tall A, Niang A, Bjerregaard-Andersen M, Løfberg SV, Seo  
642 HJ, Jeon HJ, Deerin JF, Park J, Konings F, Ali M, Clemens JD, Hughes P, Sendagala  
643 JN, Vudriko T, Downing R, Ikumapayi UN, Mackenzie GA, Obaro S, Argimon S,  
644 Aanensen DM, Page A, Keane JA, Duchene S, Dyson Z, Holt KE, Dougan G, Marks  
645 F, Baker S. The phylogeography and incidence of multi-drug resistant typhoid fever in  
646 sub-Saharan Africa. *Nature Communications* [Internet]. 2018 Dec 1 [cited 2021 Nov  
647 24];9(1). Available from: [/pmc/articles/PMC6269545/](https://pubmed.ncbi.nlm.nih.gov/30662695/)
- 648 33. Ingle DJ, Nair S, Hartman H, Ashton PM, Dyson ZA, Day M, Freedman J, Chattaway  
649 MA, Holt KE, Dallman TJ. Informal genomic surveillance of regional distribution of  
650 *Salmonella* Typhi genotypes and antimicrobial resistance via returning travellers.  
651 *PLOS Neglected Tropical Diseases* [Internet]. 2019 [cited 2021 Nov  
652 25];13(9):e0007620. Available from:  
653 <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007620>
- 654 34. Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, Harris D,  
655 Clarke L, Whitehead S, Sangal V, Marsh K, Achtman M, Molyneux ME, Cormican M,  
656 Parkhill J, MacLennan CA, Heyderman RS, Dougan G. Epidemic multiple drug  
657 resistant *Salmonella* Typhimurium causing invasive disease in sub-Saharan Africa  
658 have a distinct genotype. *Genome Research*. 2009 Dec 1;19(12):2279–87.
- 659 35. Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, Al-Mashhadani MN,  
660 Kariuki S, Msefula CL, Gordon MA, De Pinna E, Wain J, Heyderman RS, Obaro S,  
661 Alonso PL, Mandomando I, MacLennan CA, Tapia MD, Levine MM, Tennant SM,  
662 Parkhill J, Dougan G. Intracontinental spread of human invasive *Salmonella*  
663 *Typhimurium* pathovariants in sub-Saharan Africa. *Nature Genetics* 2012 44:11. 2012  
664 Sep 30;44(11):1215–21.
- 665 36. Kanteh A, Sesay AK, Alikhan NF, Ikumapayi UN, Salaudeen R, Manneh J, Olatunji  
666 Y, Page AJ, Mackenzie G. Invasive atypical non-typhoidal *Salmonella* serovars in The  
667 Gambia. *Microbial Genomics* [Internet]. 2021 Nov 23 [cited 2021 Nov  
668 24];7(11):000677. Available from:  
669 <https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000677>

- 670 37. Akullian A, Montgomery JM, John-Stewart G, Miller SI, Hayden HS, Radey MC,  
671 Hager KR, Verani JR, Ochieng JB, Juma J, Katieno J, Fields B, Bigogo G, Audi A,  
672 Walson J. Multi-drug resistant non-typhoidal Salmonella associated with invasive  
673 disease in western Kenya. *PLOS Neglected Tropical Diseases* [Internet]. 2018 Jan 1  
674 [cited 2022 May 19];12(1):e0006156. Available from:  
675 <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006156>  
676 38. Park SE, Pham DT, Pak GD, Panzner U, Espinoza LMC, Kalckreuth V von, Im J,  
677 Mogeni OD, Schütt-Gerowitt H, Crump JA, Breiman RF, Adu-Sarkodie Y, Owusu-  
678 Dabo E, Rakotozandrindrainy R, Soura AB, Aseffa A, Gasmelseed N, Sooka A, Keddy  
679 KH, May J, Aaby P, Biggs HM, Hertz JT, Montgomery JM, Cosmas L, Olack B,  
680 Fields B, Sarpong N, Razafindrabe TJL, Raminosoa TM, Kabore LP, Sampo E, Teferi  
681 M, Yeshitela B, Tayeb MA el, Krumkamp R, Dekker DM, Jaeger A, Tall A, Gassama  
682 A, Niang A, Bjerregaard-Andersen M, Løfberg SV, Deerin JF, Park JK, Konings F,  
683 Carey ME, Puyvelde S van, Ali M, Clemens J, Dougan G, Baker S, Marks F. The  
684 genomic epidemiology of multi-drug resistant invasive non-typhoidal Salmonella in  
685 selected sub-Saharan African countries. *BMJ Global Health* [Internet]. 2021 Aug 1  
686 [cited 2021 Nov 1];6(8):e005659. Available from:  
687 <https://gh.bmj.com/content/6/8/e005659>  
688 39. Gelaw AK, Nthaba P, Matle I. Detection of Salmonella from animal sources in South  
689 Africa between 2007 and 2014. *J S Afr Vet Assoc*. 2018 Nov 7;89.  
690 40. Kidanemariam A, Engelbrecht M, Picard J. Retrospective study on the incidence of  
691 Salmonella isolations in animals in South Africa, 1996 to 2006. *J S Afr Vet Assoc*  
692 [Internet]. 2010 [cited 2022 May 3];81(1):37–44. Available from:  
693 <https://journals.co.za/doi/epdf/10.10520/EJC99859>  
694 41. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-  
695 typhoidal salmonella disease: an emerging and neglected tropical disease in Africa.  
696 *The Lancet*. 2012 Jun 30;379(9835):2489–99.  
697 42. Pornsukarom S, Patchanee P, Erdman M, Cray PF, Wittum T, Lee J, Gebreyes WA.  
698 Comparative Phenotypic and Genotypic Analyses of Salmonella Rissen that  
699 Originated from Food Animals in Thailand and United States. *Zoonoses and Public*  
700 *Health* [Internet]. 2015 Mar 1 [cited 2022 May 3];62(2):151–8. Available from:  
701 <https://onlinelibrary.wiley.com/doi/full/10.1111/zph.12144>  
702 43. Xu X, Biswas S, Gu G, Elbediwi M, Li Y, Yue M. Characterization of Multidrug  
703 Resistance Patterns of Emerging Salmonella enterica Serovar Rissen along the Food  
704 Chain in China. *Antibiotics* 2020, Vol 9, Page 660 [Internet]. 2020 Sep 30 [cited 2022  
705 May 3];9(10):660. Available from: <https://www.mdpi.com/2079-6382/9/10/660/htm>  
706 44. Hoelzer K, Switt AIM, Wiedmann M. Animal contact as a source of human non-  
707 typhoidal salmonellosis. *Veterinary Research* [Internet]. 2011 Feb 14 [cited 2022 May  
708 3];42(1):1–28. Available from:  
709 <https://veterinaryresearch.biomedcentral.com/articles/10.1186/1297-9716-42-34>  
710 45. Post AS, Diallo SN, Guiraud I, Lompo P, Tahita MC, Maltha J, van Puyvelde S,  
711 Mattheus W, Ley B, Thriemer K, Rouamba E, Derra K, Deborggraeve S, Tinto H,  
712 Jacobs J. Supporting evidence for a human reservoir of invasive non-Typhoidal  
713 Salmonella from household samples in Burkina Faso. *PLOS Neglected Tropical*  
714 *Diseases* [Internet]. 2019 [cited 2022 May 3];13(10):e0007782. Available from:  
715 <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007782>  
716 46. Aoki Y, Watanabe Y, Kitazawa K, Ando N, Hirai S, Yokoyama E. Emergence of  
717 Salmonella enterica subsp. enterica serovar Chester in a rural area of Japan. *Public*  
718 *Health J Vet Med Sci* [Internet]. 2020 [cited 2022 May 3];82(5):580–4. Available  
719 from: <https://www.ncbi.nlm.nih.gov/pmc/journals/2350/>

- 720 47. Reddy EA, Shaw A v., Crump JA. Community-acquired bloodstream infections in  
721 Africa: a systematic review and meta-analysis. *The Lancet Infectious Diseases*. 2010  
722 Jun 1;10(6):417–32.
- 723 48. Harrois D, Breurec S, Seck A, Delauné A, le Hello S, Pardos de la Gándara M, Sontag  
724 L, Perrier-Gros-Claude JD, Sire JM, Garin B, Weill FX. Prevalence and  
725 characterization of extended-spectrum  $\beta$ -lactamase-producing clinical *Salmonella*  
726 *enterica* isolates in Dakar, Senegal, from 1999 to 2009. *Clinical Microbiology and*  
727 *Infection*. 2014 Feb 1;20(2):O109–16.
- 728 49. Qiu YF, Nambiar RB, Xu X bin, Weng ST, Pan H, Zheng KC, Yue M. Global  
729 Genomic Characterization of *Salmonella enterica* Serovar Telelkebir. *Frontiers in*  
730 *Microbiology*. 2021 Jul 29;12:2007.
- 731 50. Sokaribo AS, Perera SR, Sereggela Z, Krochak R, Balezantis LR, Xing X, Lam S,  
732 Deck W, Attah□poku S, Abbott DW, Tamuly S, White AP. A GMMA-CPS-Based  
733 Vaccine for Non-Typhoidal *Salmonella*. *Vaccines* 2021, Vol 9, Page 165 [Internet].  
734 2021 Feb 17 [cited 2022 Apr 29];9(2):165. Available from:  
735 <https://www.mdpi.com/2076-393X/9/2/165/htm>
- 736 51. Tamamura Y, Tanaka K, Uchida I. Characterization of pertussis-like toxin from  
737 *Salmonella* spp. that catalyzes ADP-ribosylation of G proteins. *Scientific Reports* 2017  
738 7:1. 2017 Jun 1;7(1):1–13.
- 739 52. den Bakker HC, Moreno Switt AI, Govoni G, Cummings CA, Ranieri ML, Degoricija  
740 L, Hoelzer K, Rodriguez-Rivera LD, Brown S, Bolchacova E, Furtado MR, Wiedmann  
741 M. Genome sequencing reveals diversification of virulence factor content and possible  
742 host adaptation in distinct subpopulations of *Salmonella enterica*. *BMC Genomics*.  
743 2011 Dec 22;12(1):1–11.
- 744 53. Mezal EH, Bae D, Khan AA. Detection and functionality of the CdtB, PltA, and PltB  
745 from *Salmonella enterica* serovar Javiana. *Pathogens and Disease*. 2014 Nov  
746 1;72(2):95–103.
- 747 54. Rodriguez-Rivera LD, Bowen BM, Den Bakker HC, Duhamel GE, Wiedmann M.  
748 Characterization of the cytolethal distending toxin (typhoid toxin) in non-typhoidal  
749 *Salmonella* serovars. *Gut Pathogens*. 2015 Jul 24;7(1):1–7.
- 750 55. Chang SJ, Jin SC, Jiao X, Galan JE. Unique features in the intracellular transport of  
751 typhoid toxin revealed by a genome-wide screen. *PLOS Pathogens*.  
752 2019;15(4):e1007704.
- 753 56. Marcus SL, Brumell JH, Pfeifer CG, Finlay BB. *Salmonella* pathogenicity islands: big  
754 virulence in small packages. *Microbes and Infection*. 2000 Feb 1;2(2):145–56.
- 755 57. Hensel M. Evolution of pathogenicity islands of *Salmonella enterica*. *International*  
756 *Journal of Medical Microbiology*. 2004 Sep 24;294(2–3):95–102.
- 757 58. Seth-Smith HMB. SPI-7: *Salmonella*'s Vi-Encoding Pathogenicity Island. *The Journal*  
758 *of Infection in Developing Countries* [Internet]. 2008 Aug 1 [cited 2022 May  
759 4];2(04):267–71. Available from: <https://jidc.org/index.php/journal/article/view/220>
- 760 59. Shah DH, Lee MJ, Park JH, Lee JH, Eo SK, Kwon JT, Chae JS. Identification of  
761 *Salmonella gallinarum* virulence genes in a chicken infection model using PCR-based  
762 signature-tagged mutagenesis. *Microbiology (N Y)* [Internet]. 2005 Dec 1 [cited 2022  
763 May 4];151(12):3957–68. Available from:  
764 <https://www.microbiologyresearch.org/content/journal/micro/10.1099/mic.0.28126-0>
- 765 60. Webber B, Borges KA, Furian TQ, Rizzo NN, Tondo EC, dos Santos LR, Rodrigues  
766 LB, do Nascimento VP. Detection of virulence genes in *Salmonella Heidelberg*  
767 isolated from chicken carcasses. *Revista do Instituto de Medicina Tropical de São*  
768 *Paulo* [Internet]. 2019 Jul 22 [cited 2022 May 4];61. Available from:  
769 <http://www.scielo.br/j/rimtsp/a/6QcGt7kdBnqKGxbyBxXTjtn/?lang=en&format=html>

- 770 61. Panzenhagen PHN, Cabral CC, Suffys PN, Franco RM, Rodrigues DP, Conte-Junior  
771 CA. Comparative genome analysis and characterization of the Salmonella  
772 Typhimurium strain CCRJ\_26 isolated from swine carcasses using whole-genome  
773 sequencing approach. *Letters in Applied Microbiology* [Internet]. 2018 Apr 1 [cited  
774 2022 May 4];66(4):352–9. Available from:  
775 <https://onlinelibrary.wiley.com/doi/full/10.1111/lam.12859>  
776 62. Cherchame E, Guillier L, Lailler R, Vignaud ML, Jourdan-Da Silva N, le Hello S,  
777 Weill FX, Cadel-Six S. Salmonella enterica subsp. enterica Welikade: guideline for  
778 phylogenetic analysis of serovars rarely involved in foodborne outbreaks. *BMC*  
779 *Genomics* [Internet]. 2022 Dec 1 [cited 2022 May 4];23(1):1–13. Available from:  
780 <https://link.springer.com/articles/10.1186/s12864-022-08439-2>  
781 63. Kingsley RA, Humphries AD, Weening EH, de Zoete MR, Winter S,  
782 Papaconstantinopoulou A, Dougan G, Bäumlér AJ. Molecular and phenotypic analysis  
783 of the CS54 island of Salmonella enterica serotype Typhimurium: Identification of  
784 intestinal colonization and persistence determinants. *Infection and Immunity* [Internet].  
785 2003 Feb 1 [cited 2022 May 4];71(2):629–40. Available from:  
786 <https://journals.asm.org/doi/full/10.1128/IAI.71.2.629-640.2003>  
787 64. Kombade S, Kaur N. Pathogenicity Island in *Salmonella*. *Salmonella spp -*  
788 *A Global Challenge* [Internet]. 2021 Mar 11 [cited 2022 May 4]; Available from:  
789 <https://www.intechopen.com/chapters/75674>  
790 65. WHO. WHO recommends use of first typhoid conjugate vaccine [Internet]. 2018  
791 [cited 2021 Nov 26]. Available from: [https://www.who.int/news/item/03-04-2018-](https://www.who.int/news/item/03-04-2018-who-recommends-use-of-first-typhoid-conjugate-vaccine)  
792 [who-recommends-use-of-first-typhoid-conjugate-vaccine](https://www.who.int/news/item/03-04-2018-who-recommends-use-of-first-typhoid-conjugate-vaccine)  
793  
794

795

796

797 **Figure Legends**

798 Fig 1: Epidemiological information showing: (A) number of *Salmonella* isolated received  
799 from the different sentinel hospitals at different years, and (B) Number of different  
800 *Salmonella* serotypes received from the different sentinel hospitals.

801

802 Fig 2: Grape tree showing core genome MLST of *S. Typhi* from human sources in Africa,  
803 deposited in the EnteroBase database. Red leaf labels are genomes from this study

804

805 Fig 3: SNP-phylogeny based tree and gene presence/absence showing the genomic profile of  
806 *Salmonella* Typhi genomes retrieved from 5 sentinel laboratories in Nigeria. ARGs: antibiotic  
807 resistance genes, STs: Sequence types

808

809 Fig 4: SNP-phylogeny based tree and gene presence/absence map showing the genomic  
810 profile of *Salmonella* Enteritidis retrieved from 3 sentinel laboratories in Nigeria. ARGs:  
811 antibiotic resistance genes, STs: Sequence types.

812

813 Fig 5. Gene presence/absence map showing the genomic profile of non-typhoidal *Salmonella*  
814 retrieved from 5 sentinel laboratories in Nigeria. ARGs: antibiotic resistance genes, STs:  
815 Sequence types

816

817 Fig 6: Frequency of occurrence of *Salmonella* pathogenicity island in TS (Typhoidal  
818 *Salmonella*) and NTS (Non-typhoidal *Salmonella*) in this study.

819















